News
MedPage Today on MSN2d
Another Biologic Reduces COPD ExacerbationsMepolizumab (Nucala) helped prevent exacerbations of chronic obstructive pulmonary disease (COPD) when added to background ...
Chronic obstructive pulmonary disease ... also considers your individual symptoms and history of acute exacerbations. As the disease progresses, you’re more susceptible to complications ...
Phase III trial data published in The New England Journal of Medicine support Nucala’s role as an add-on biologic therapy to ...
The findings, published in The Lancet Respiratory Medicine, suggest that dupilumab, when used alongside standard triple ...
A new study published in the journal of BMC Pulmonary Medicine showed that dyspnea (mMRC score 1.67), symptom load (CAT score ...
Verywell Health on MSN3d
Exposure to Air Pollution and Extreme Weather Can Increase COPD RiskMore people may be at risk for developing COPD due to exposure to environmental irritants, such as heat waves and air ...
GSK has highlighted approval of Nucala in COPD as one of its top 2025 priorities, adding to its established medicines for the ...
News-Medical.Net on MSN1d
Virtual pulmonary rehabilitation proves to be safe and effective for COPD patientsVirtual pulmonary rehabilitation is a safe, effective alternative to traditional pulmonary rehabilitation programs for people ...
GSK announced on Thursday that its monoclonal antibody ‘Nucala’, or mepolizumab, delivered a statistically significant and ...
AstraZeneca's Breztri met primary goals in four asthma trials, including KALOS, LOGOS, LITHOS, and VATHOS, involving over ...
Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis, published ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback